# Pea Protein Satiety Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/pea-protein-satiety-randomized-trial-evidence-review
Category: evidence-review
Summary: Pea Protein Satiety Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are ra
Last reviewed: 2026-06-25
Reviewed by: Migaku Evidence Review
# Pea Protein Satiety Randomized Trial: What the Evidence Says

## Quick Answer

Pea Protein Satiety Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 randomized trial, 1 research article.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Pea protein preload improves postprandial glucose response in healthy adults: a randomized, double-blind, controlled pilot study | randomized trial | 2 | 2026-06-11 | 10.1007/s00394-026-03971-3 |
| A novel fasting mimetic (Mimio) creates fasting-like benefits to hunger control, oxidative stress, and cardiometabolic health in humans. | research article | 4 | 2026-02-20 | 10.1038/s41598-026-38495-7 |

## What The Sources Report

- Elevated postprandial glucose levels are consistently associated with increased cardiovascular risk, even in normoglycaemic individuals. [Elbira Arig (2026); evidence level 2]
- A novel fasting mimetic (Mimio) creates fasting-like benefits to hunger control, oxidative stress, and cardiometabolic health in humans. [Grant AD (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For pea protein satiety randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Elbira Arig (2026). Pea protein preload improves postprandial glucose response in healthy adults: a randomized, double-blind, controlled pilot study. DOI: 10.1007/s00394-026-03971-3. PMCID: PMC13260030. PMID: 42274793. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13260030/
- Grant AD (2026). A novel fasting mimetic (Mimio) creates fasting-like benefits to hunger control, oxidative stress, and cardiometabolic health in humans.. DOI: 10.1038/s41598-026-38495-7. PMCID: PMC12953901. PMID: 41720867. https://pmc.ncbi.nlm.nih.gov/articles/PMC12953901/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.